FAS and neoplasm: We analyzed the correlation between FAS mRNA expression and the sensitivity of different tumor cell lines to target drugs for NSCLC (vemurafenib, dabrafenib, crizotinib and carbozantinib), pancreatic cancer (erlotinib) and breast cancer (afatinib).